Captrust Financial Advisors Acquires 1,854 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Captrust Financial Advisors grew its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 24.5% in the third quarter, HoldingsChannel.com reports. The fund owned 9,433 shares of the medical research company’s stock after purchasing an additional 1,854 shares during the period. Captrust Financial Advisors’ holdings in Exact Sciences were worth $643,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of EXAS. Chicago Partners Investment Group LLC lifted its position in Exact Sciences by 1.7% in the third quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company’s stock valued at $651,000 after purchasing an additional 158 shares during the last quarter. Amalgamated Bank lifted its position in Exact Sciences by 2.7% in the second quarter. Amalgamated Bank now owns 10,937 shares of the medical research company’s stock valued at $462,000 after purchasing an additional 284 shares during the last quarter. Huntington National Bank lifted its position in Exact Sciences by 838.1% in the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 352 shares during the last quarter. CIBC Asset Management Inc lifted its position in Exact Sciences by 6.2% in the second quarter. CIBC Asset Management Inc now owns 6,118 shares of the medical research company’s stock valued at $258,000 after purchasing an additional 356 shares during the last quarter. Finally, Diversified Trust Co lifted its position in Exact Sciences by 3.6% in the second quarter. Diversified Trust Co now owns 10,337 shares of the medical research company’s stock valued at $437,000 after purchasing an additional 357 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on EXAS shares. Piper Sandler lowered their price objective on Exact Sciences from $85.00 to $75.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. BTIG Research boosted their target price on Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Jefferies Financial Group boosted their target price on Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Craig Hallum reduced their target price on Exact Sciences from $82.00 to $65.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Finally, Robert W. Baird reduced their target price on Exact Sciences from $70.00 to $67.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $75.29.

Insiders Place Their Bets

In related news, EVP Brian Baranick sold 929 shares of the stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the completion of the sale, the executive vice president now owns 12,758 shares in the company, valued at approximately $893,060. This trade represents a 6.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin T. Conroy purchased 19,500 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were purchased at an average price of $51.35 per share, with a total value of $1,001,325.00. Following the acquisition, the chief executive officer now directly owns 1,074,191 shares in the company, valued at $55,159,707.85. This represents a 1.85 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.36% of the company’s stock.

Exact Sciences Trading Up 2.6 %

Exact Sciences stock opened at $63.16 on Thursday. The company has a market capitalization of $11.69 billion, a price-to-earnings ratio of -53.98 and a beta of 1.24. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62. The business’s fifty day simple moving average is $62.95 and its two-hundred day simple moving average is $56.60.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. The firm had revenue of $708.66 million during the quarter, compared to the consensus estimate of $716.80 million. Exact Sciences’s revenue for the quarter was up 12.8% compared to the same quarter last year. As a group, equities analysts predict that Exact Sciences Co. will post -1.13 earnings per share for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.